Business Wire03.01.19
OptraSCAN, an on-demand digital pathology solution provider, has expanded its Medical Advisory Board with two key appointments—
Dr. Thomas J. Montine, M.D., Ph.D., chairman, Department of Pathology at Stanford University School of Medicine; and Dr. Jon S. Morrow, M.D., Ph.D., chairman, Department of Pathology at Yale School of Medicine.
Other than the newly added medical advisors, OptraSCAN’s Medical Advisory Board includes Dr. Jiaoti Huang, M.D., Ph.D., professor and chairman, Department of Pathology at Duke University, who is also chairing the board; Dr. Allen Gown, M.D., founder and medical director at Phenopath; and Dr. Abul Abbas, M.D., chairman, Department of Pathology at University of California, San Francisco.
“I am delighted to join the OptraSCAN Medical Advisory Board. Digital imaging will transform our discipline over the next five to 10 years. OptraSCAN’s goal to bring this capability to all pathologists, regardless of the size of their practice, will be an important enabler of this transformation. My participation reflects my commitment to seeing this goal achieved,” said Dr. Morrow.
“Like the team at OptraSCAN, I am enthusiastic about the great potential of digital pathology to transform the practice of pathology and enhance access to highest quality biopsy evaluation for patients across the globe. I am pleased to join the Medical Advisory Board of OptraSCAN and I look forward to working together,” said Dr. Montine.
“OptraSCAN is fortunate to receive an overwhelming support from such prestigious institutions and distinguished thought leaders in a short span of its incorporation,” said Abhi Gholap, founder and CEO, OptraSCAN. “We value the advice and collaboration from these highly regarded experts as we continue to march ahead in our mission to provide affordable digital pathology for the benefit of every human.”
Dr. Huang said, “Dr. Morrow and Dr. Montine are visionary academic and practice leaders in the field of pathology. I am sure their valuable advice to OptraSCAN will benefit the company’s products and solutions to meet the needs of pathologists in the era of digital pathology.”
An ISO 13485 certified company and CE -arked whole slide scanners for IVD use, OptraSCAN has developed world’s first "On-Demand Digital Pathology" System; focused on delivering fully integrated, affordable systems and solutions. These serve as the perfect tool for transition from conventional microscopy to digital pathology for the acquisition of whole slide images, viewing, storing, real time sharing, and reporting via on-demand or outright purchase model.
OptraSCAN’s Digital Pathology system comprises of small-footprint, low and high throughput WSI scanners; well equipped for confocal, brightfield, fluorescence and frozen sections/live view mode, an integrated image viewer and image management system IMAGEPath, image analysis OptraASSAYS, a cloud-based LIMS (CLOUDPath), and CARDS (computer-aided region detection system). OptraSCAN’s integrated solutions include TELEPath, a telepathology solution and AI and ML-based automated image analysis solutions that have been developed to provide accurate assessment of nuclear and membrane biomarker, immuno-oncology and prostate cancer.
Other than the newly added medical advisors, OptraSCAN’s Medical Advisory Board includes Dr. Jiaoti Huang, M.D., Ph.D., professor and chairman, Department of Pathology at Duke University, who is also chairing the board; Dr. Allen Gown, M.D., founder and medical director at Phenopath; and Dr. Abul Abbas, M.D., chairman, Department of Pathology at University of California, San Francisco.
“I am delighted to join the OptraSCAN Medical Advisory Board. Digital imaging will transform our discipline over the next five to 10 years. OptraSCAN’s goal to bring this capability to all pathologists, regardless of the size of their practice, will be an important enabler of this transformation. My participation reflects my commitment to seeing this goal achieved,” said Dr. Morrow.
“Like the team at OptraSCAN, I am enthusiastic about the great potential of digital pathology to transform the practice of pathology and enhance access to highest quality biopsy evaluation for patients across the globe. I am pleased to join the Medical Advisory Board of OptraSCAN and I look forward to working together,” said Dr. Montine.
“OptraSCAN is fortunate to receive an overwhelming support from such prestigious institutions and distinguished thought leaders in a short span of its incorporation,” said Abhi Gholap, founder and CEO, OptraSCAN. “We value the advice and collaboration from these highly regarded experts as we continue to march ahead in our mission to provide affordable digital pathology for the benefit of every human.”
Dr. Huang said, “Dr. Morrow and Dr. Montine are visionary academic and practice leaders in the field of pathology. I am sure their valuable advice to OptraSCAN will benefit the company’s products and solutions to meet the needs of pathologists in the era of digital pathology.”
An ISO 13485 certified company and CE -arked whole slide scanners for IVD use, OptraSCAN has developed world’s first "On-Demand Digital Pathology" System; focused on delivering fully integrated, affordable systems and solutions. These serve as the perfect tool for transition from conventional microscopy to digital pathology for the acquisition of whole slide images, viewing, storing, real time sharing, and reporting via on-demand or outright purchase model.
OptraSCAN’s Digital Pathology system comprises of small-footprint, low and high throughput WSI scanners; well equipped for confocal, brightfield, fluorescence and frozen sections/live view mode, an integrated image viewer and image management system IMAGEPath, image analysis OptraASSAYS, a cloud-based LIMS (CLOUDPath), and CARDS (computer-aided region detection system). OptraSCAN’s integrated solutions include TELEPath, a telepathology solution and AI and ML-based automated image analysis solutions that have been developed to provide accurate assessment of nuclear and membrane biomarker, immuno-oncology and prostate cancer.
